About
AUROBAC THERAPEUTICS
AUROBAC THERAPEUTICS is a biopharmaceutical company founded in 2022 by three highly renowned life sciences innovation companies, Boehringer Ingelheim, Evotec SE and bioMérieux, to develop the next generation of precision medicines addressing the medical needs associated with the development of antimicrobial resistance and infectious diseases.
The company is building a pipeline of drug candidates for hospitalized patients, associated with rapid diagnostics to identify pathogens and their resistance mechanisms.
This 40 million euros-funded joint-venture plans to cover the entire value chain of projects from R&D, including clinical development, to registration and commercialization
AUROBAC is currently seeking to strengthen its product portfolio and is particularly interested in in-licensing or co-developing products developed to fight bacterial infections & AMR, with a focus on:
- New and alternative modalities like e.g., phage lysins, therapeutic antibodies, etc.,
- Novel target classes and mode of actions,
- Host Immune-modulation approaches,
- Products addressing high unmet medical needs,
- Targeted modalities that can be combined with rapid and actionable diagnostics and that are supported by new economic models.
“The rise of antimicrobial resistance worldwide jeopardizes the prevention and treatment of life-threatening resistant bacterial infections, which are already killing 1.3 million people per year. AUROBAC has the remarkable ambition to become a leader in AMR innovation with a unique combination of the best capabilities of the three founding companies, Boehringer Ingelheim, Evotec and bioMérieux.
Our strategy is to develop and commercialize safe and effective drugs using selected diagnostic approaches, in order to cure efficiently infected patients with minimized risks of recurrence and limited impact on disseminating resistance.“
Florence Séjourné, CEO.